Famotidine

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-22-R-0119

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The Defense Logistics Agency (DLA) Troop Support has announced a forthcoming solicitation for a national requirements contract to supply Famotidine tablets, as detailed under procurement identifier SPE2D2-22-R-0119. This presolicitation notice outlines the agency’s intent to establish a firm-fixed price, requirements-type contract with a one-year base period and four additional one-year option periods. The contract is designed to ensure a reliable, national supply source for Famotidine, supporting the pharmaceutical needs of the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. Orders will be fulfilled through the DLA and VA prime vendor programs. The scope of this procurement encompasses the supply of Famotidine tablets in multiple strengths and packaging configurations. Specifically, the contract will cover 20 mg tablets in bottles of 25, 30, 50, 90, 180, and 1000 counts, as well as 40 mg tablets in bottles of 100, 180, and 1000 counts. These items are classified as commercial products and will be solicited in accordance with FAR Part 12 procedures. The acquisition is unrestricted and fully competitive, inviting proposals from all qualified sources engaged in pharmaceutical preparation manufacturing, as defined by NAICS code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version). The applicable Product Service Code is 6505. The primary objective of this procurement is to secure a consistent and cost-effective supply of Famotidine for federal healthcare and correctional institutions, ensuring uninterrupted access to this essential medication. The contract will be structured as a requirements contract under FAR 52.216-21, meaning the government will order quantities as needed, with annual usage estimates to be provided in the solicitation’s Schedule of Supplies. Interested contractors should note that this is a commercial item acquisition and that all responsible sources may submit a proposal for consideration. There are no set-aside restrictions; the opportunity is open to all qualified vendors. The solicitation will be posted on the DLA Bid Board System (DIBBS) and on SAM.gov, with the projected release date currently set for August 2022, though DLA reserves the right to adjust this timeline. For further information or to submit questions and comments, interested parties are encouraged to contact the designated contracting officers: Kristen Baraniewicz ([email protected], 215-737-4484) or Jason Wray ([email protected], 215-737-0614). Contractors are also advised to set up automated notifications on the DIBBS and SAM.gov platforms to stay informed of any updates or changes to the solicitation. This opportunity represents a significant, long-term contract for pharmaceutical manufacturers and distributors with the capacity to meet national-level requirements for Famotidine, and aligns with the federal government’s ongoing commitment to ensuring the availability of critical medications across its healthcare and correctional systems.